Medications, which target and protect the bone from complications of metastasis, have been related with osteonecrosis of the jaw, a potentially serious lesion. The concurrent use of those medications ...[Read more]

The US Food and Drug Administration approved first immunotherapy drug for Triple-Negative Breast Cancer Until recently, women with inoperable triple-negative breast cancer had one treatment option: c...[Read more]

Cancer patients undergoing treatment experience a variety of symptoms throughout therapy, that can have negative effects on their quality of life. Patients are faced not only with the physical side-ef...[Read more]

Breast cancer survivors experience a range of physical, psychological, and relational sexual health issues that affect their quality of life. They may feel depression, anxiety, body image concerns, an...[Read more]

Tele-Oncology and Digital Health ● Let’s Talk About Sex, Sexual Health and Oncofertility, ● Life after Cancer - Cancer Survivorship, Technology for Care ● Treatment Toxicities – What Patients Report ...[Read more]

The immense progress in molecular biology has contributed in the development of new anticancer drugs, which target specific cellular targets and molecules. This has led to an important progress in can...[Read more]

The MASCC/ISOO Annual Meeting on Supportive Care in Cancer The 2019 Annual Meeting of the Multidisciplinary Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Onco...[Read more]

The 2nd International Symposium on medication related osteonecrosis of the jaws in Copenhagen took place in 2 November 2018 [www.righospitalet.dk/MRONJ]. The medications which are related to MRONJ are...[Read more]